Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Evommune, Inc.

EVMN

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Last trade $7.12
Day change +$0.02 (+0.28%)
Day range $6.79 – $8.29
Volume 598,812
Market cap $294M

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$293.58M
Price / earnings
—
Price / book
1.17×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.05×

Profitability

Earnings per share
-$2.73
Return on assets
-40.63%
Return on equity
-44.98%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
8.52×
Quick ratio
8.52×
Cash ratio
2.32×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$91M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for EVMN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025
Revenue$0$0$0$0
Cost of revenue$0$0$0$0
Gross profit$0$0$0$0
Selling, general and administrative$8.78M$8.48M$6.64M$9.31M
Research and development$24.55M$26.41M$17.32M$20.4M
Total operating expenses$33.33M$34.9M$23.95M$29.72M
Operating income-$33.33M-$34.9M-$23.95M-$29.72M
Interest expense$0$0-$4K$0
Income before taxes-$30.88M-$32.25M-$21.67M-$28.27M
Income taxes$0$0$0$0
Net income-$30.88M-$32.25M-$21.67M-$28.27M
Net income attributable to common shareholders-$30.88M-$32.25M-$21.67M-$28.27M
EBITDA-$32.79M-$34.34M-$23.61M-$29.39M
Basic earnings per share-$0.85-$0.89-$0.64-$1.42
Diluted earnings per share-$0.85-$0.89-$0.64-$1.42

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Pelthos Therapeutics Inc. (PTHS) Reports Q3 Loss, Lags Revenue Estimates

Pelthos Therapeutics reported a Q3 loss of $3.09 per share, missing consensus estimates of $2.83 loss, and posted revenues of $15.4 million, falling 15.34% short of expectations. Despite the miss, the company showed improvement from a year-ago loss of $5.3 per share. The stock has declined 69.7% year-to-date while the S&P 500 gained 11.3%. Zacks assigned the stock a Rank #2 (Buy) rating based on favorable estimate revision trends ahead of the earnings release.

GlobeNewswire Inc.

Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight

The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.